Asia Oceania Journal of Nuclear Medicine and Biology

Asia Oceania Journal of Nuclear Medicine and Biology

Prognostic utility of interim 18F-FDG PET/CT after two cycles of ABVD in response assessment in Hodgkin’s lymphoma patients: single-center preliminary experience

Document Type : Original Article

Authors
Nguyen Quang Toan 1, 2
Pham Van Thai 1
Le Thanh Dung 3
Mai Hong Son 4
Pham Lam Son 2
Do Huyen Nga 2
Le Van Quang 1, 2
Le Ngoc Ha 4
1 Department of Nuclear Medicine, National Cancer Hospital and Hanoi Medical University, Hanoi, Vietnam
2 Department of Oncology, National Cancer Hospital and Hanoi Medical University, Hanoi, Vietnam
3 Department of Radiology, Viet Duc Hospital, Hanoi, Vietnam
4 Department of Nuclear Medicine, 108 Military Hospital, Hanoi, Vietnam
10.22038/aojnmb.2025.89081.1644
Abstract
Objective(s): This study evaluates the utility of interim 18F-FDG PET/CT (iPET)-guided therapy in a Southeast Asian population, addressing gaps in region-specific data. Key outcomes included treatment response rates and progression-free survival (PFS) stratified by iPET results (Deauville score (DS) 1-3 vs. 4-5) across all clinical risk groups (including early-stage favorable/unfavorable and advanced-stage based on the International Prognostic Score (IPS)). Findings will inform optimal risk-adapted strategies in resource-aware settings.
Methods: A prospective study was conducted of 100 patients with Hodgkin Lymphoma (HL) at the Vietnam National Cancer Hospital from March 2020 to March 2024. All patients underwent baseline clinical assessment and imaging (CT and/or PET/CT), followed by two cycles of ABVD chemotherapy. IPET was performed for early response assessment using Deauville scores (DS), with subsequent treatment adjusted according to NCCN guidelines.
Results: A total of 100 patients with classical Hodgkin lymphoma (mean age: 32±13.8 years; range 9-73) were analyzed. Bulky disease and extranodal involvement were observed in 10.0% and 15.0% of cases, respectively. Early-stage disease (stage I-II) was present in 72.0%, and advanced-stage (stage III-IV) in 28.0%. After two cycles of ABVD, 78.0% of patients had a negative iPET result (DS 1-3), of whom 88.5% were DS 1, while 22.0% had a positive iPET result (DS 4-5), predominantly DS 4 (72.7%). In early-stage disease, the 3-year progression-free survival (PFS) was significantly higher in the favorable group than in the unfavorable group (95.7% vs. 81.2%, p=0.03). In advanced-stage disease, low-risk (IPS 0–3) patients achieved a 3-year PFS of 88.2%, whereas high-risk (IPS 4-7) patients had a markedly lower PFS of 42.9% (p<0.001). Overall, patients with negative iPET had substantially better 3-year PFS than those with positive iPET (93.6% vs. 40.9%, p<0.0001). The predictive performance of iPET for treatment outcomes showed a sensitivity of 72.3%, specificity 89.0%, PPV 59.0%, NPV 93.6%, and overall accuracy 86.0% (95% CI 0.78-0.91). Diagnostic accuracy remained high across subgroups, ranging from 84.0% in early-stage disease to 89.5% in advanced-stage, and was highest in favorable early-stage (90.8%) and low-risk advanced-stage (93.7%) patients. In multivariate analysis, iPET was identified as an independent predictor of PFS (p<0.05).
Conclusion: In a real-world Vietnamese cohort with Hodgkin lymphoma, interim PET/CT guided by Deauville scoring after two cycles of ABVD chemotherapy showed strong predictive value for treatment response. The results advocate for broader integration of NCCN-consistent risk-adapted strategies in Southeast Asia.
Keywords
Interim 18F-FDG PET/CT
Early response treatment
Progression-Free Survival
Hodgkin’s Lymphoma
Subjects
  1. Sung H, Ferlay J, Siegel RL, Laversanne M, Soerjomataram I, Jemal A, et al. Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA: A Cancer Journal for Clinicians. 2021; 71(3): 209-49.
  2. Huang J, Pang WS, Lok V, Zhang L, Lucero-Prisno III DE, Xu W, et al. Incidence, mortality, risk factors, and trends for Hodgkin lymphoma: a global data analysis. Journal of hematology & oncology. 2022; 15(1): 57.
  3. Bacher U, Binder M. Modifying therapy in patients with advanced Hodgkin’s lymphoma by integrating early metabolic response by interim PET-CT. Annals of Translational Medicine. 2016; 4(Suppl1): S19.
  4. Cerci JJ, Pracchia LF, Linardi CC, Pitella FA, Delbeke D, Izaki M, et al. 18F-FDG PET after 2 cycles of ABVD predicts event-free survival in early and advanced Hodgkin lymphoma. Journal of Nuclear Medicine. 2010; 51(9): 1337-43.
  5. Al-Ibraheem A, Mottaghy FM, Juweid ME. PET/CT in Hodgkin lymphoma: an update. In Seminars in Nuclear Medicine. 2023; 53(3): 303-319.
  6. Omar NN, Alotaify LM, Abolela MS. PET/CT in initial staging and therapy response assessment of lymphoma. The Egyptian Journal of Radiology and Nuclear Medicine. 2016; 47(4): 1639-1647.
  7. Yassin A, El Sheikh RH, Ali MM. PET/CT vs CECT in assessment of therapeutic response in lymphoma. Egyptian Journal of Radiology and Nuclear Medicine. 2020; 51(1):238.
  8. Hoppe RT, Advani RH, Ai WZ, Ambinder RF, Armand P, Bello CM, et al. NCCN Guidelines® Insights: Hodgkin Lymphoma, Version 2.2022. Journal of the National Comprehensive Cancer Network. 2022; 20(4): 322-334.
  9. Eichenauer DA, Aleman BM, André M, Federico M, Hutchings M, Illidge T, et al. Hodgkin lymphoma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow- Annals of Oncology. 2018; 29: iv19-29.
  10. Gallamini A, Hutchings M, Rigacci L, Specht L, Merli F, Hansen M, Pet al. Early interim 2-[18F] fluoro-2-deoxy-D-glucose positron emission tomography is prognostically superior to international prognostic score in advanced-stage Hodgkin's lymphoma: a report from a joint Italian-Danish study. Journal of Clinical Oncology. 2007; 25(24): 3746-52.
  11. Spaepen K, Stroobants S, Dupont P, Vandenberghe P, Thomas J, de Groot T, et al. Early restaging positron emission tomography with 18F-fluorodeoxyglucose predicts outcome in patients with aggressive non-Hodgkin’s lymphoma. Annals of Oncology. 2002; 13(9): 1356-63.
  12. Donzel M, Bonjour M, Combes JD, Broussais F, Sesques P, Traverse-Glehen A, et al. Lymphomas associated with Epstein-Barr virus infection in 2020: Results from a large, unselected case series in France. eClinical Medicine. 2022; 54: 101674.
  13. Gallamini A, Barrington SF, Biggi A, Chauvie S, Kostakoglu L, Gregianin M, et al. The predictive role of interim positron emission tomography for Hodgkin lymphoma treatment outcome is confirmed using the interpretation criteria of the Deauville five-point scale. Haematologica. 2014; 99(6): 1107.
  14. Al-Ibraheem A, Anwer F, Juweid ME, Shagera QA, Khalaf AN, Obeidat S, et al. Interim FDG-PET/CT for therapy monitoring and prognostication in Hodgkin’s Lymphoma. Scientific Reports. 2022; 12(1): 17702.
  15. Gobbi PG, Ferreri AJ, Ponzoni M, Levis A. Hodgkin lymphoma. Critical Reviews in Oncology/Hematology. 2013; 85(2): 216-37.
  16. Diefenbach CS, Li H, Hong F, Gordon LI, Fisher RI, Bartlett NL, Crump M, Gascoyne RD,Wagner Jr H, Stiff PJ, Cheson BD. Evaluation of the International Prognostic Score (IPS‐7) and a Simpler Prognostic Score (IPS‐3) for advanced Hodgkin lymphoma in the modern era. British Journal of Haematology. 2015; 171(4): 530-8.
  17. Elhamady HY, Mostafa HM, Elsayed HF, Abo-ElAzm OM, Hussein MH. Deauville score versus ratio Deauville score in the interpretation of interim 18F-FDG PET-CT and in prediction of outcome in children with FDG-avid extra-nodal lymphomas. Egyptian Journal of Radiology and Nuclear Medicine. 2022; 53(1): 217.
  18. Boellaard R, Delgado-Bolton R, Oyen WJ, Giammarile F, Tatsch K, Eschner W, et al. FDG PET/CT: EANM procedure guidelines for tumour imaging: version 2.0. European Journal of Nuclear Medicine and Molecular Imaging. 2015; 42(2): 328-54.
  19. Seshachalam A, Karpurmath SV, Rathnam K, Raman SG, Janarthinakani M, Prasad K, et al. Does interim PET scan after 2 cycles of ABVD predict outcome in Hodgkin lymphoma? Real-world evidence. Journal of Global Oncology. 2019; 5:1-3.
  20. Seshachalam A, Karpurmath SV, Rathnam K, Srinivasan A, Scott J, SG R, et al. Role of interim PET scan after 2 cycles of ABVD in pediatric Hodgkin Lymphoma: Retrospective multicenter study from South India. Indian Journal of Medical and Paediatric Oncology. 2021; 42(05): 415-25.
  21. Gobbi PG, Zinzani PL, Broglia C, Comelli M, Magagnoli M, Federico M, et al. Comparison of prognostic models in patients with advanced Hodgkin disease: Promising results from integration of the best three Cancer: Interdisciplinary International Journal of the American Cancer Society. 2001; 91(8): 1467-78.
  22. Fuchs M, Goergen H, Kobe C, Kuhnert G, Lohri A, Greil R, et al. Positron emission tomography–guided treatment in early-stage favorable Hodgkin lymphoma: final results of the international, randomized phase III HD16 trial by the German Hodgkin Study Group. Journal of Clinical Oncology. 2019; 37(31):2835-45.
  23. Hutchings M, Loft A, Hansen M, Pedersen LM, Buhl T, Jurlander J, et al. FDG-PET after two cycles of chemotherapy predicts treatment failure and progression-free survival in Hodgkin lymphoma. Blood. 2006; 107(1): 52-9.
  24. Cheson BD, Horning SJ, Coiffier B, Shipp MA, Fisher RI, Connors JM, et al. Report of an international workshop to standardize response criteria for non-Hodgkin's lymphomas. Journal of Clinical Oncology.1999; 17(4): 1244.
  25. Gallamini A, Rigacci L, Merli F, Nassi L, Bosi A, Capodanno I, et al. The predictive value of positron emission tomography scanning performed after two courses of standard therapy on treatment outcome in advanced stage Hodgkin's disease. Haematologica. 2006; 91: 475-81.
  26. Metser U, Mohan R, Beckley V, Moshonov H, Hodgson D, Murphy G. FDG PET/CT Response Assessment Criteria for Patients with Hodgkin’s and Non-Hodgkin’s Lymphoma at End of Therapy: A Multiparametric Approach. Nuclear Medicine and Molecular Imaging. 2016; 50(1):46-53.
  27. Cheson BD, Fisher RI, Barrington SF, Cavalli F, Schwartz LH, Zucca E, et al. Recommendations for initial evaluation, staging, and response assessment of Hodgkin and non-Hodgkin lymphoma: the Lugano classification. Journal of Clinical Oncology. 2014; 32(27): 3059-67.
  28. Zinzani PL, Rigacci L, Stefoni V, Broccoli A, Puccini B, Castagnoli A, et al. Early interim 18F-FDG PET in Hodgkin’s lymphoma: evaluation on 304 patients. European Journal of Nuclear Medicine and Molecular Imaging. 2012; 39(1): 4-12.
  29. Liu HL, Wang MC, Kuo CY, Ma MC, Liao CK. Using Interim Positron Emission Tomography as a Predictor for Relapse-Free Survival in Hodgkin Lymphoma: Experience from a Single Institution. Journal of Cancer Research and Practice. 2021; 8(4):134.
  30. Kelly KM, Cole PD, Pei Q, Bush R, Roberts KB, Hodgson DC, et al. Response‐adapted therapy for the treatment of children with newly diagnosed high risk Hodgkin lymphoma (AHOD0831): a report from the Children’s Oncology Group. British Journal of Haematology. 2019; 187(1): 39-48.
  31. Radford J, Illidge T, Counsell N, Hancock B, Pettengell R, Johnson P, et al. Results of a trial of PET-directed therapy for early-stage Hodgkin’s lymphoma. New England Journal of Medicine. 2015; 372(17):1598-607.
Asia Oceania Journal of Nuclear Medicine and Biology
Volume 14, Issue 1
January 2026
Pages 79-89